- Recommendation ID
- NG245/1
- Question
What is the clinical and cost-effectiveness of regular 'fixed-dose' inhaled corticosteroid (ICS) regimens (using SABA [short-acting beta2 agonist] as a reliever) compared with 'as-needed' strategies (for example ICS/formoterol) as the initial standard treatment for asthma in children aged 5 to 11 years?
- Any explanatory notes
(if applicable) For a short explanation of why the committee made this recommendation for research, see the rationale and impact section on medicines for initial management in children aged 5 to 11 .
Full details of the evidence and the committee's discussion are in evidence review P: drug classes for initial asthma management.
Source guidance details
- Comes from guidance
- Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN)
- Number
- NG245
- Date issued
- November 2024
Other details
Is this a recommendation for the use of a technology only in the context of research? | No |
Is it a recommendation that suggests collection of data or the establishment of a register? | No |
Last Reviewed | 28/01/2025 |